Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-06-11

Clinical Trial Update: A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update indicating the MAESTRO-NASH-OUTCOMES study of resmetirom in patients with well-compensated NASH cirrhosis is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Resmetirom (resmetirom)

Snippet

Sponsor: Madrigal Pharmaceuticals, Inc. | Conditions: NASH, Cirrhosis, Liver | Phase 3 | Status: ACTIVE_NOT_RECRUITING